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related myeloid neoplasm with t(5;14)(q33;q32)
after treatment for acute promyelocytic leukemia
Hoon-Gu Kim1, Ja-Hyun Jang4 and Eun-Ha Koh2,3*Abstract
Background: Therapy-related myeloid neoplasm after treatment for acute promyelocytic leukemia (APL) is a relatively
infrequent but severe complication. Most therapy-related myeloid neoplasms after treatment for APL are classified as
therapy-related myelodysplastic syndrome or therapy-related acute myeloid leukemia. Translocation of 5q31-33,
PDGFRB occur rarely in therapy-related myeloid neoplasm and there has been two identified PDGFRB partner genes
located at 14q32, TRIP11 and KIAA1509.
Results: The TRIP11-PDGFRB fusion was identified in a patient with therapy-related myeloid neoplasm with t(5;14)
(q33;q32) after treatment of APL using conventional cytogenetics, fluorescence in situ hybridization (FISH) and
molecular methods. Cytogenetic analysis of the bone marrow aspirate revealed 46, XY, t(5;14)(q33;q32) in all 20
analyzed cells. No other cytogenetic abnormalities were observed. Break-apart FISH analysis demonstrated that
rearrangement of PDGFRB at 5q33 was positive in 460 of 500 cells analyzed, while the PML-RARA rearrangement
remained undetectable by RT-PCR. Sequencing of RT-PCR products revealed fusion between exon 16 of TRIP11
and exon 11 of PDGFRB. However, the KIAA1509-PDGFRB fusion was not detected by RT-PCR.
Conclusion: We firstly demonstrated that therapy-related myeloid neoplasm with TRIP11-PDGFRB fusion was identified
after treatment of APL.
Keywords: PDGFRB, TRIP11, Therapy-related myeloid neoplasm, Acute promyelocytic leukemia, t(5;14)(q33;32)Background
Therapy-related myeloid neoplasms (t-MNs) are late
complications of cytotoxic therapies used to treat ma-
lignant and non-malignant conditions. The incidence of
t-MNs is increasing worldwide, due to improved sur-
vival rates following treatment of primary malignancies
[1]. t-MNs account for 10-20% of all malignant myeloid
diagnoses [2].
The introduction of all trans retinoic acid (ATRA) has
been a major breakthrough in the treatment of acute
promyelocytic leukemia (APL), characterized by t(15;17)
(q22;q12). The combination of ATRA and anthracycline-
based chemotherapy results in high rates of complete* Correspondence: ehkohmd@gnu.ac.kr
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unless otherwise stated.remission and survival. However, ATRA combined with
chemotherapeutic drugs increases the risk of t-MN.
Most t-MNs after treatment for APL are classified as
therapy related myelodysplastic syndrome (t-MDS) or
therapy related acute myeloid leukemia (t-AML). Re-
arrangement of platelet-derived growth factor receptor
beta (PDGFRB) is a distinctive type of myeloid neo-
plasm which occurs rarely in t-MN. More than 20 dif-
ferent partner genes of PDGFRB have been described
[3]. The most common abnormality is the t(5;12)(q31 ~
33;p12), which forms an ETV6-PDGFRB fusion gene.
The TRIP11-PDGFRB fusion gene and the KIAA1509
(HGNC approved gene symbol; CCDC88C)-PDGFRB
fusion gene were identified in a patient with myelopro-
liferative neoplasm (MPN) and t(5;14)(q33;q32) [4,5]. t-
MN has an extremely poor clinical outcome. However,
t-MNs with PDGFRB rearrangement are very sensitive
to imatinib methylate, a tyrosine kinase inhibitor with
activity against ABL, c-KIT, and PDGFR [6].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 RT-PCR using primers located in TRIP11 exons 14-16
and PDGFRB exons 11-12 resulting in amplification of TRIP11-
PDGFRB fusion transcripts. M: Molecular weight marker, lane 1; 5′
TRIP11 and 3′ PDGFRB specific primers (patient), lane 2; Replication of
5′ TRIP11 and 3′ PDGFRB specific primers (patient), lane 3; 5′ TRIP11
and 3′ PDGFRB specific primers (control), lane 4; 5′ KIAA1509 and 3′
PDGFRB specific primers (patient), lane 5; 5′ KIAA1509 and 3′ PDGFRB
specific primers (control).
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fusion in a patient with t-MN with t(5;14)(q33;q32) after
treatment of APL.
Case presentation
A 54-year-old Korean male was referred to our hospital
due to hematemesis in July of 2010. Peripheral blood re-
sults showed a hemoglobin of 9.1 g/dL, a platelet count
of 23 × 109/L, and a leukocyte count of 1.3×109/L with
30% abnormal promyelocytes. The bone marrow aspi-
rates and biopsy showed hypercellular marrow with 95%
abnormal promyelocytes, including faggot cells. Karyo-
typic analysis of the bone marrow revealed 46, XY, t
(15;17) (q22;21) in all 20 metaphases that were analyzed.
No other cytogenetic abnormalities were observed. The
PML-RARA fusion gene was detected using RT-PCR and
FISH analysis. A diagnosis of acute promyelocytic
leukemia with t(15;17) (q22;21);PML-RARA was made
based on the World Health Organization (WHO) 2008
classification of myeloid lymphoid neoplasms. The pa-
tient was treated with ATRA in combination with idaru-
bicin. The presence of the PML-RARA rearrangement
was monitored by FISH and quantitative RT-PCR. He
achieved a complete remission. The patient received
consolidation and maintenance chemotherapies. He was
monitored at regular time intervals and no PML-RARA
was detected in the bone marrow after consolidation
and maintenance therapies. At a regular follow-up ana-
lysis in October 2013, peripheral blood results showed a
hemoglobin of 12.3 g/dL, a platelet count of 104 × 109/
L, and a leukocyte count of 19.8×109/L, with 58% neu-
trophils and 5% eosinophils. The bone marrow aspirates
showed myeloid hyperplasia with eosinophils and eosino-
phil precursors (13%) without blast excess (1%). Karyo-
typic analysis of the bone marrow revealed 46, XY, t(5;14)
(q33;q32) in 20 metaphase cells. The PDGFRB rearrange-
ment was detected by FISH analysis, while the PML-
RARA rearrangement remained undetectable by RT-
PCR. Since there has been two identified PDGFRB part-
ner genes located at 14q32, TRIP11 and KIAA1509
(http://atlasgeneticsoncology.org), RT-PCR analysis was
performed to specify the partner gene. As a result,
TRIP11-PDGFRB fusion transcript, not KIAA1509-
PDGFRB was detected (Figures 1 and 2). A final diag-
nosis of t-MN with t(5;14)(q33;q32) and a TRIP11-
PDGFRB rearrangement was made.
Methods
Conventional cytogenetic analysis and FISH analysis
Chromosomes were analyzed with GTG-banding and the
karyotype was described according to the International Sys-
tem for Human Cytogenetics Nomenclature, 2013. FISH
analysis was conducted using a dual color PDGFRB breaka-
part probe (5q33, D5S1907, centromere side, red signal/D5S2014, telomere side, green color). The manufacturer’s
recommendations were followed for the hybridization and
post-washing procedures (Abbott Molecular/Vysis, Des
Plaines, IL, USA). The expected normal signal pattern is
two red/green fusion signals. When cells have PDGFRB
gene rearrangement, the fusion signal would be split into a
red and a green signal.
Molecular methods
To determine whether TRIP11 or KIAA1509 were fused
to PDGFRB, RNA extraction was performed with the
Qiamp RNA Blood Mini Kit (Qiagen, Hilden, Germany).
Reverse transcription was performed with random hexam-
ers and MMLV reverse transcriptase (Life Technologies,
NY, USA). RT-PCR was performed with Takara LA Taq
DNA polymerase (Takara Bio Inc, Shiga, Japan). For the
detection of fusion transcript between TRIP11 and
PDGFRB, 5′ TRIP11 and 3′ PDGFRB specific primers
were used as previously described [4], using 1407CF
(5′-CGCTGCAGCTTTCTGTCTCTCAGGAACAAG-3′)
and 2022PR (5′-GTAACGTGGCTTCTTCTGCCA-3′).
RT-PCR was performed with ABI 2720 (Life Technologies,
Foster City, CA, USA) and cycles were as follows: initial
denaturation at 94°C for 1 min; then 35 cycles of 94°C
for 30 sec, 60°C for 30 sec and 72°C for 2 min; and a
final extension of 5 min at 72°C. Direct sequencing of
amplified products was performed with ABI 3130 (Life
Technologies). Sequences were analyzed using Sequencher
software (version 4.10 Gene Codes Corporation, Ann
Arbor, MI, USA). For the detection of a fusion transcript
between KIAA1509 and PDGFRB, 5′ KIAA1509 and 3′
TRIP11 PDGFRB
Figure 2 Sequence chromatogram of the TRIP11-PDGFRB fusion junction showing the fusion between exon 16 of TRIP11 and exon 11
of PDGFRB. Black arrows indicate the location of primers. The white arrow indicates the location of breakage and reunion. E: exon.
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scribed [5], using KIAA1509-RTF1 (5′-ccgggacacagataagac-
3′) and PDGFRB-RTR1 (5′-catgatcttcagctccgaca-3′).
Results and discussion
We have identified a TRIP11-PDGFRB fusion in a pa-
tient with t(5;14)(q33;q32) after treatment for APL.
Cytogenetic analysis of a bone marrow aspirate revealed
46, XY, t(5;14)(q33;q32) in 20 analyzed cells. Break-apart
FISH analysis demonstrated that rearrangement of
PDGFRB at 5q33 was positive in 460 of 500 cells ana-
lyzed. Sequencing of RT-PCR products revealed fusion be-
tween exon 16 of TRIP11 (NM_004239.3) and exon 11 of
PDGFRB (NM_002609.3), which is the same breakage and
reunion point as that reported in the previous study [4].
The KIAA1509-PDGFRB fusion gene was not detected by
RT-PCR (Figures 1 and 2). t-MN after treatment for APL is
an infrequent but severe complication. The incidence of t-
MN was 1% - 6.5% [7,8]. t-MDS is a more common com-
plication than t-AML when considering t-MNs [7-9]. The
most common cytogenetic abnormalities were partial and
complete deletions of chromosomes 5 and 7, and 11q23 re-
arrangements. Translocation of 5q31-33 and PDGFRB
occur rarely in t-MN. The PDGFRB gene at 5q33 is nor-
mally expressed in erythroid and myeloid precursors in the
bone marrow, and it is a receptor tyrosine kinase which
plays an important role in wound healing and other pro-
cesses in adults [10,11]. PDGFRB is disrupted by other
translocations, such as t(5;12), or t(5;14). The most com-
mon abnormality is t(5;12)(q31-33;p12), which forms an
ETV6-PDGFRB fusion gene. The ETV-PDGFRB fusion
gene was identified in patients with chronic myelomonocy-
tic leukemia (CMML) and translocation t(5;12)(q33;p13)
by Golub and Gilliland in 1994 [12]. ETV-PDGFRB is a
chimeric tyrosine kinase protein which is constitutively
active due to enforced homodimerization by self-
association domains present on the fusion partner pro-
tein (ETV6). This in turn activates downstreamsignaling pathways, resulting in cell proliferation and
survival [13]. Levin et al. cloned KIAA1509 as a
PDGFRB fusion partner in imatinib-responsive myelo-
proliferative disease associated with t(5;14)(q33;q32)[5].
Expression of the CEV14-PDGFRB fusion gene has
been reported in acute myeloid leukemia with t(7;11)
after clonal evolution [4] in one reported case of t-MN
after treatment for AML. Abe et al. hypothesized that
the CEV14-PDGFRB fusion causes ectopic constitutive
tyrosine kinase activation of PDGFRB, leading to trans-
formation via the ras signal transduction pathway [4].
CEV14 is homologous to TRIP11, which was isolated as
one of the proteins that interacts with thyroid hormone
receptors in the presence of T3. In our case, response
to therapy was monitored by FISH and RT-PCR for the
PML-RARA rearrangement. At his last regular follow-
up, RT-PCR for PML-PARA was negative, and eosino-
philia was mild. Eosinophilia has been reported in
recurrent chromosomal aberrations. 5q31-33 is often
involved in myeloid disorders with eosinophilia, suggest-
ing involvement of a PDGFRB rearrangement. t(5;14)(q33;
q32) was detected with conventional cytogenetics and
FISH analysis for PDGFRB was positive. In order to iden-
tify partner genes of PDGFRB, such as KIAA1509 or
TRIP11, we performed RT-PCR and direct sequencing for
both. We have identified a TRIP11-PDGFRB rearrange-
ment. Detection of PDGFRB rearrangement is important
because these rearrangements respond well to treatment
with imatinib mesylate [6].
The majority of abnormalities involving PDGFRB are
detected by conventional cytogenetics. Performing con-
ventional cytogenetics on a regular basis in all treated
APL patients for the early detection of t-MNs implied by
chromosomal aberrations is important.
Conclusion
This is the first report of t-MN with a TRIP11-PDGFRB
rearrangement after treatment of APL.
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